Business
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every time, dramatically raising the probability of success. WARREN, N.J., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced significant progress in the development of its proprietary PredicTcell™ platform, designed to accelerate precision
About this update from Tevogen Bio Holdings Inc.
[{"type":"image","alt":"Tevogen Bio Inc","displaySize":"","headline":null,"caption":"Tevogen Bio Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/5d67b8c6f92b49048a1dc80d97a6164f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kuP3e9ZLQ.FWmrA1GfPG6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5d67b8c6f92b49048a1dc80d97a6164f","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Potential future T cell therapies could reliably bind to their target nearly every time, dramatically raising the probability of success. ","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":253,"olType":false},{"type":"text","content":"WARREN, N.J., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced significant progress in the development of its proprietary PredicTcell™ platform, designed to accelerate precision immunotherapy development and efficacy through advanced machine learning and transformer-based models. The platform is being developed with the support of Microsoft (Nasdaq: MSFT) and Databricks, leveraging their advanced cloud and data technologies to enable scalability and efficiency.","length":534,"tagName":"p"},{"type":"text","content":"The alpha version of PredicTcell was trained on more than 124,000 records using transformer-based architecture and 91,000 records using traditional machine learning architecture. The alpha version of the model delivered recall levels of ~92–97% and a precision range of ~38–43%, serving as a proof-of-concept for AI-driven prediction of immunologically active peptide-T cell receptor interactions.","length":397,"tagName":"p"},{"type":"text","content":"Informed by insights from Tevogen’s proprietary ExacTcell™ platform and positive Phase 1 trial results, PredicTcell Beta aims for significantly higher precision in identifying virology targets. Key advancements include:","length":219,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Expanded the training d...